Fractionated Urinary Cytology in the Follow-up of Bladder Cancer

1990 ◽  
Vol 66 (1) ◽  
pp. 40-41 ◽  
Author(s):  
K. J. HASTIE ◽  
R. AHMAD ◽  
C. U. MOISEY
Keyword(s):  
Bladder Cancer ◽  
Urinary Cytology

Screening for bladder cancer

2017 ◽  
Author(s):  
Maree Brinkman ◽  
Maurice Zeegars
Keyword(s):  
Bladder Cancer ◽  
Screening Tools ◽  
Treatment Modalities ◽  
Urinary Cytology ◽  
Urological Malignancies ◽  
Increased Risk ◽  
Urological Symptoms ◽  
Disease Specific Mortality ◽  
Asymptomatic Individuals

Bladder cancer (BC) is one of the most common urological malignancies and ranks ninth among all cancers worldwide. While screening has the potential to detect early cases of BC and reduce disease specific mortality, to date there are no routine screening programmes of asymptomatic individuals conducted anywhere in the world. There are however, a range of tests and procedures available for the detection and subsequent diagnosis of BC for select individuals presenting with urological symptoms and who are at increased risk of the disease.This chapter provides an overview of the traditional screening tools used for the detection of BC, such as urinalysis for haematuria and urinary cytology, as well as a brief description of follow-up procedures including cystoscopy, imaging, and treatment modalities.

Bladder Cancer to Patients Younger than 30 Years: A Retrospective Study and Review of the Literature

2017 ◽  
Vol 84 (4) ◽  
pp. 231-235 ◽  
Author(s):  
Ioannis Katafigiotis ◽  
Stavros Sfoungaristos ◽  
Alberto Martini ◽  
Konstantinos Stravodimos ◽  
Ioannis Anastasiou ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Risk Factor ◽  
Retrospective Study ◽  
Radical Cystectomy ◽  
Young Patients ◽  
Multimodality Treatment ◽  
Urinary Cytology ◽  
Macroscopic Hematuria ◽  
Multiple Recurrences

Objectives The aim of this report was to study the specific characteristics of bladder cancer in patients younger than 30 years. Materials and Methods Five patients with a mean age of 24 ± 2.83 years were included in the study. All patients had painless macroscopic hematuria as the first symptom. Three patients had pTa as a first diagnosis, one had pT1 and one pT2. All the patients had smoking as a risk factor and at least one additional possible risk factor. Results One patient with pTa had an aggressive course and after multiple recurrences was diagnosed with pT2 and refused to be submitted to radical cystectomy and died from the disease even though he received a multimodality treatment. The other two patients with the pTa diagnosis had no recurrence after the first TUR-BT and the patient with the pT1 diagnosis after one recurrence with a pTa histology is free of recurrence for the last 2 years. The patient diagnosed with pT2 was submitted to a radical cystectomy and an s-pouch diversion with a preservation of the genital system in order to have the ability of a future motherhood with the acceptance of course risks. Conclusions Young patients with bladder cancer is a difficult group of patients and show more reluctance to comply to the necessary strict follow-up of the repeated urinary cytology examinations, cystoscopies and CT pyelographies. Herein, we report a retrospective study of five patients younger than 30 years with bladder cancer.

Flow Cytometry Analysis in Voided Urine of Patients with Bladder Cancer

1993 ◽  
Vol 60 (2) ◽  
pp. 162-166
Author(s):  
A. Lotto ◽  
G. Carluccio ◽  
A. Calisti ◽  
A. Disperati ◽  
E. Capuzzo ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Bladder Cancer ◽  
Quantitative Evaluation ◽  
Dna Content ◽  
Urine Cytology ◽  
Urinary Cytology ◽  
Flow Cytometry Analysis ◽  
Excellent Correlation ◽  
First Diagnosis

Flow cytometry is known to be able to give a quantitative evaluation of the DNA of cellular populations (grade of ploidy), as well as to estimate the percentages of phases (S + G2M) providing useful information about the pathology in question and its aggressivity. This method has been applied in diagnosing patients with bladder cancer, using their voided urine and comparing with urine cytology. Our data, from 59 patients, indicate flow cytometry utility in diagnosing bladder cancer; in fact there is an excellent correlation between the urinary cytology and the DNA content in cytometry which increases in higher grade bladder cancer. The sensitivity of CFM is in the range of 92% to 94%, and is superior to that of conventional voided urine cytology (range 64% to 84%). It is felt that cytofluorometric analysis permits a reliable evaluation of voided urine, not only at first diagnosis, but especially during follow-up.

scholarly journals Significance of urinary cytology in the treatment evaluation and follow-up of patients with bladder cancer.

1995 ◽  
Vol 34 (4) ◽  
pp. 773-779
Author(s):  
Makoto MOTOI ◽  
Toru KURASHIGE ◽  
Mariko MORI ◽  
Yoshie FUJIWARA ◽  
Wataru MURAKAMI ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Treatment Evaluation ◽  
Urinary Cytology

Single-arm phase I/II study of the safety and efficacy of OncoTherad immunomodulator in patients BCG-refractory or relapsed non-muscle invasive bladder cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e16000-e16000
Author(s):  
Wagner José Fávaro ◽  
Sonia Regina Iantas ◽  
Juliana Mattoso Gonçalves ◽  
Eduardo Augusto Rabelo Socca ◽  
Nelson Duran ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Phase I ◽  
Tumor Recurrence ◽  
Invasive Bladder Cancer ◽  
Intravesical Therapy ◽  
Urinary Cytology ◽  
Effective Treatment Option ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

e16000 Background: There is no effective intravesical second-line therapy for high-grade non-muscle-invasive bladder cancer (HGNMIBC) when Bacillus Calmette-Guerin (BCG) fails. In this scenario, a new perspective is represented by OncoTherad immunomodulator. OncoTherad is a nanostructured inorganic phosphate complex associated to glycosidic protein, developed by University of Campinas/ Brazil, which exhibits antitumor properties. The aims of the study were to evaluate the efficacy and safety of OncoTherad immunomodulator for BCG-refractory or relapsed HGNMIBC. Methods: We carried out a prospective, single-center (Municipal Hospital of Paulinia, São Paulo, Brazil), single-arm phase I/II study in 15 (10 male, 5 female) consecutive patients with HGNMIBC-refractory or relapsed (≥ 1 previous course of BCG intravesical therapy). Patients with muscle-invasive disease were excluded. OncoTherad regimen consisted of an induction course of 6 weekly intravesical instillations followed by a maintenance course of 1 monthly instillation until completing 1 year of treatment. Follow-up was performed with systematic mapping biopsies of the bladder, cystoscopy, ultrasound and urinary cytology. The primary endpoint was recurrence-free survival (RFS) rate, and secondary endpoint was safety response. The recurrence was defined as histology proven tumor recurrence (any grade), and monitored at 3-month intervals. Results: The median age and follow-up were 71 years and 14.0 months, respectively. A 14-months RFS rate in all patients was 86.7%. Only 2 patients (13.3%) showed recurrence during follow-up, however these patients showed incipient malignant lesions (downstaging of pT1G3 to pTaG1). Regarding toxicity, we reported moderate adverse systemic event of hypersensitivity to OncoTherad in 2 patients (13.3%), and minimal local side effects (dysuria and cystitis)in 6 patients (40.0%). Conclusions: In conclusion, OncoTherad seems a safe and effective treatment option for BCG-refractory or relapsed HGNMIBC patients and may provide benefit for preventing tumor recurrence. We report a RFS rate of 86.7% (14.0 months), potentially avoiding or postponing the need for radical surgery in these patients. Clinical trial information: CAAE: 93619718.7.0000.5404.

FISH Assay for THE Detection of Bladder Cancer

2005 ◽  
Vol 72 (4) ◽  
pp. 457-460
Author(s):  
P.F. Bassi ◽  
V. De Marco ◽  
C. Lamon ◽  
F. Longo ◽  
A. Volpe ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Histological Examination ◽  
Chromosomal Abnormalities ◽  
Transitional Cell ◽  
Urinary Cytology ◽  
Positive Cytology ◽  
Non Invasive ◽  
Urothelial Tumors

We evaluated the sensitivity and specificity of fluorescence in situ hybridization (FISH) performed on the urine specimens of patients under follow-up for superficial bladder cancer. Thirty-seven patients were enrolled and underwent cystoscopy, urinary cytology or biopsy and FISH examination. Urinary cytology and FISH were evaluated in exfoliated urothelial cells from bladder washings. A mixture of fluorescent labeled probes to the centromere of chromosomes 3, 7 and 17, and locus 9p21 was used to assess urinary cells for chromosomal abnormalities indicative of malignancy. Nine patients (24.3%) showed an abnormal cystoscopy, but only five patients showed transitional cell carcinoma at histology. Eighteen patients (48.6%) showed an abnormal FISH: one patient (2.7%) had a positive cytology, and three patients (8.1%) showed an atypical cytology. Patients with both positive cystoscopy and histological examination had a positive FISH, while only one patient had a positive cytology. Patients with positive cystoscopy and negative histological examination had a negative FISH. Three patients with negative cystoscopy and suspicious cytology had a positive FISH. Ten patients (27%) with both negative cystoscopy and cytology had a positive FISH. The sensitivity of the FISH assay was 100%, 50% for the cytology and 62% for the cystoscopy. The specificity of the FISH assay, cytology and cystoscopy were 66%, 100% and 86%, respectively. The sensitivity of the FISH assay in detecting non-invasive urothelial tumors is worth further studies.

Prediction of tumor recurrence in patients in follow up for bladder cancer with suspicious urinary cytology using molecular and cytogenetic approaches

2019 ◽  
Vol 18 (1) ◽  
pp. e305
Author(s):  
R. Montalbo ◽  
M. Ingelmo-Torres ◽  
L. Izquierdo ◽  
J. Montadas ◽  
M. Sole ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Tumor Recurrence ◽  
Urinary Cytology

scholarly journals The performance of the Xpert Bladder Cancer Monitor Test and voided urinary cytology in the follow-up of urinary bladder tumors

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Tomaz Smrkolj ◽  
Urska Cegovnik Primozic ◽  
Teja Fabjan ◽  
Sasa Sterpin ◽  
Josko Osredkar
Keyword(s):  
Bladder Cancer ◽  
Urinary Bladder ◽  
Negative Predictive Value ◽  
Predictive Value ◽  
Cancer Surveillance ◽  
Urinary Cytology ◽  
Time Intervals ◽  
Histopathological Results ◽  
Bladder Tumours

AbstractBackgroundCystoscopy in complement with urinary cytology represents the gold standard for the follow-up of patients with urinary bladder tumours. Xpert Bladder Cancer Monitor Test (XBC) is a novel mRNA-based urine test for bladder cancer surveillance. The aim of the study was to evaluate the performance of the XBC and voided urinary cytology (VUC) in the follow-up of bladder tumours.Patients and methodsThe XBC was performed on stabilized voided urine and VUC was performed on urine samples. The results were compared to cystoscopic findings and histopathological results after transurethral resection of the bladder lesion.ResultsFor the prediction of malignant histopathological result sensitivity, the specificity and negative predictive value were 76.9%, 9 7.5% and 93.0% for the XBC and 38.4%, 9 7.5% and 83.3%, respectively for VUC. For the prediction of suspicious or positive cystoscopic finding sensitivity, the specificity and negative predictive value were 75.0%, 95.2%, and 93.0% respectively for the XBC and 41.7%, 97.6%, and 85.4% for VUC. The sensitivities for papilary urothelial neoplasms of low malignant potential (PUNLMP), low- and high-grade tumours were 0.0%, 66.7% an d 100.0% for the XBC and 0.0%, 66 .7% and 42.9%, respectively for VUC.ConclusionsThe XBC showed significantly higher overall sensitivity and negative predictive value than VUC and could be used to increase the recommended follow-up cystoscopy time intervals. Complementing the XBC and voided urinary cytology does not improve performance in comparison to the XBC alone.

scholarly journals Diagnosis of Bladder Cancer with Urinary Cytology, Immunocytology and DNA-Image-Cytometry1

2001 ◽  
Vol 22 (3) ◽  
pp. 103-109 ◽  
Author(s):  
Bernhard Planz ◽  
Christian Synek ◽  
Thomas Deix ◽  
Alfred Böcking ◽  
Michael Marberger
Keyword(s):  
Bladder Cancer ◽  
Transitional Cell ◽  
High Sensitivity ◽  
Image Cytometry ◽  
Urinary Cytology ◽  
Urothelial Cells ◽  
Lewis X ◽  
Consensus Report ◽  
Dna Image Cytometry

DNA‐image‐cytometry and antibodies directed against the Lewis X‐ and the 486p 3/12 antigen were applied to improve diagnostic accuracy of urinary cytology for the detection of bladder cancer. Cytology, immunocytology and DNA‐image‐cytometry were performed in spontaneously voided urine samples and barbotage bladder washings from 71 patients. The DNA content was determined using the CM‐1 Cytometer according to the recommendation of the ESCAP Consensus Report on Standardization of DNA‐image‐cytometry (1995). For immunocytological examination we used the monoclonal anti Lewis X antibody P‐12 and antibody 486p 3/12. All patients underwent subsequent cystoscopy and for any suspicious lesion biopsy or transurethral resection was done. Histological findings revealed 31 patients with transitional cell carcinomas of different stages and grades of malignancy. 40 patients had various benign diseases of the urinary bladder. Cytology yielded a sensitivity of 68% and a specificity of 100%. DNA aneuploidy was detected in 81% of cancer patients with a specificity of 100%. By combination of these two methods the overall sensitivity increased to 87%. Immunocytology with Lewis X and 486p 3/12 antibodies showed reactivity in 84% and 87% in combination with a specificity of 80% and 70%, respectively. By combining urinary cytology, immunocytology and/or DNA‐image‐cytometry the overall sensitivity increased to 94% with no change in specificity. DNA‐image‐cytometry should be used to evaluate particularly urothelial cells suspicious for malignancy in urinary specimens. Because of low specificity the monoclonal antibodies against Lewis X‐ and 486p 3/12 antigens are not helpful in screening for bladder cancer. Nevertheless, their high sensitivity may justify their use in case DNA image cytometry is not available and in the follow up of patients with transitional cell carcinoma.

Sign in / Sign up

Export Citation Format

Share Document